secwatch.observer — SEC 8-K summary
======================================

Issuer:     Evofem Biosciences, Inc. (EVFM)
CIK:        0001618835
Form:       8-K
Filed at:   2023-08-14T23:59:59+00:00
Accession:  0001493152-23-028670
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Evofem Q2 net product sales fall 59% to $2.5M; reduces operating expenses 68%
-----------------------------------------------------------------------------

- Net product sales $2.5M, down 59% YoY; $1.6M in product returns of short-dated shelf life impacted revenue.
- Total operating expenses decreased 68% to $9.8M; selling & marketing down 82% to $2.2M.
- Net loss improved to $8.6M ($5.43/share) from $124.1M loss ($580.48/share) in prior year Q2.
- Cash at June 30, 2023: $0.6M, down from $4.8M at Dec 31, 2022; raised $1.0M in July and $0.5M in August via convertible notes.
- Filed Series E-1 Preferred Stock; investors exchanged $1.8M notes for 1,800 shares convertible at $0.40 per share.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1618835/000149315223028670/0001493152-23-028670-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1618835/000149315223028670/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-028670

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer